

# Transforming Lives Through the Promise of Genetic Medicine

CORPORATE OVERVIEW | 2H 2026



**Geovanna**  
Living with Recessive Dystrophic  
Epidermolysis Bullosa

**Abeona Therapeutics** is a commercial-stage biopharmaceutical company that is dedicated to developing cell and gene therapies for severe and life-threatening diseases.

Working together to deliver cell and gene therapies for people impacted by serious diseases.

## Proven Expertise in Cell and Gene Therapy

Abeona is a fully integrated cell and gene therapy company that leverages its vast scientific research and drug development expertise to create, develop, manufacture and deliver life-changing genetic medicines. Led by an experienced management team with a track record of launching and commercializing novel therapies, including autologous gene therapies, both in the U.S. and globally, Abeona is well-positioned to advance efficacious and safe therapeutics that transform the lives of people impacted by devastating diseases.

## Advancing and Commercializing Innovative Cell and Gene Therapies

At Abeona, we are working to commercialize differentiated therapies that redefine the standard of care for severe, life-threatening diseases.

## At a Glance

### HEADQUARTERS

Cleveland, OH

### NASDAQ

ABEO

### MANAGEMENT TEAM

**Vishwas Seshadri, Ph.D., M.B.A.**

*Chief Executive Officer, Director*

**Gianine Esposito**

*Chief People Officer*

**Brian Kevany, Ph.D.**

*Senior Vice President, Chief Technical Officer and Chief Scientific Officer*

**Brendan O'Malley, J.D., Ph.D.**

*Chief Legal Officer*

**Mohamad Tabrizi, M.S., M.B.A.**

*Chief Business Officer*

**Madhav Vasanthavada, Ph.D., M.B.A.**

*Senior Vice President, Chief Commercial Officer*

**Joseph Vazzano**

*Chief Financial Officer*

**Megan Callan**

*Vice President, Head Of Quality*

**Carl Denny**

*Senior Vice President, Regulatory Affairs*

**Greg Gin**

*Vice President, Investor Relations and Corporate Communications*

**James Gow, MD, MBA, MS, MHCM**

*Senior Vice President, Clinical Development and Medical Affairs*

**Amanda Moore, MSHS**

*Vice President, Program Leadership and Clinical Operations*

## ABEONA PROGRAMS

PRECLINICAL PHASE 1/2 PHASE 3 APPROVED

**pz-cel**  
(brand name ZEVASKYN®)  
Recessive dystrophic epidermolysis bullosa (RDEB)



**PSMA-SIR™**  
ABO-701 (Advanced prostate cancer)



## ABEONA PROGRAMS

PRECLINICAL PHASE 1/2 PHASE 3 APPROVED

**UX111\***  
Sanfilippo syndrome type A (MPS IIIA)  
Ultragenyx



**TSHA-102\***  
Rett syndrome  
Taysha Gene Therapies



\*These are intended pivotal trials to support regulatory submission.

### ZEVASKYN (prademagene zamikeracel)

To learn more, please visit [ZEVASKYN.com](https://www.zevaskyn.com).

### PSMA-SIR-T (ABO-701)

Metastatic prostate cancer remains a leading cause of cancer mortality, with more than 30,000 deaths annually in the U.S. despite multiple prior lines of therapy. PSMA-SIR-T, a first-in-class engineered autologous T-cell therapy, has demonstrated in preclinical studies durable tumor control, specificity to PSMA, and a modest cytokine release profile: a favorable safety signal absent in current cell therapy approaches. Its purpose-built SIR design is completely new, engineered to overcome the core failures of cell therapy. To learn more about SIR T [click here](#) to watch a webinar from Dr. Preet Chaudhary, MD PhD, professor of Medicine at Keck School of Medicine at USC.

### UX111 | Partnered with Ultragenyx

CNS-targeted therapy for MPS IIIA. UX111 is a gene therapy for Sanfilippo syndrome type A (MPS IIIA), designed to correct SGSH enzyme deficiency. It targets the CNS to reduce heparan sulfate accumulation, aiming to slow neurodevelopmental and physical decline.

### TSHA-102 | Partnered with Taysha Gene Therapies

MECP2 regulation for Rett syndrome. TSHA-102 is an AAV9-based therapy delivered intrathecally for Rett syndrome. It features miRARE technology to regulate MECP2 expression cell-by-cell, minimizing the risk of overexpression in the CNS.

REV 2026MAY12